Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Supernus Pharmaceuticals achieves record revenues, faces generic competition in 2022

Supernus Pharmaceuticals delivered a strong financial performance in 2022, driven by record revenues and successful product launches.
While facing challenges from generic competition, the company's focus on growth brands and pipeline assets offers opportunities for future expansion and innovation.
Strategic financial management and market adaptation will be crucial for Supernus Pharmaceuticals to navigate challenges and capitalize on growth prospects in 2023.
With a solid financial foundation and a commitment to innovation, the company is poised to pursue growth opportunities and enhance shareholder value in the pharmaceutical sector.

Supernus Pharmaceuticals reports Q1 revenue growth, faces Trokendi XR challenges

Supernus Pharmaceuticals delivered a mixed performance in Q1 2023, with strong revenue but challenges in Trokendi XR sales.
The company's financial strength, strategic guidance revisions, and pipeline progress position it for future growth.
Opportunities lie in leveraging cash reserves, driving key product sales, and advancing pipeline programs for sustained growth.
Addressing challenges in Trokendi XR sales and maintaining competitive positioning will be crucial for Supernus Pharmaceuticals' success.

Supernus Pharmaceuticals reports Q2 growth driven by Qelbree success

Supernus Pharmaceuticals showcased strong performance in Q2 2023, driven by Qelbree and GOCOVRI growth, despite Trokendi XR sales decline.
While facing challenges with Trokendi XR, the company's pipeline progress and strategic focus on key products offer growth opportunities.
Management's financial guidance reiteration for 2023 reflects confidence in the company's ability to navigate challenges and capitalize on strengths.
Overall, Supernus Pharmaceuticals remains positioned for growth through product innovation and market expansion strategies.

Supernus Pharmaceuticals reports robust Q3 performance amidst revenue challenges

Supernus Pharmaceuticals delivered a strong performance in Q3 2023 driven by Qelbree and GOCOVRI, showcasing revenue growth and promising product milestones.
While facing challenges with Trokendi XR sales decline and financial losses, the company maintains a positive outlook with revised full-year guidance and a solid cash position.
Opportunities lie in leveraging product strengths, advancing pipeline studies, and utilizing available resources to sustain growth and navigate challenges effectively.

Supernus Pharmaceuticals reports robust earnings, eyes CNS market expansion

Supernus Pharmaceuticals delivered strong financial performance in Q4 2023 and full year 2023, supported by record sales and stable earnings.
The company's transition to growth products, strong cash reserves, and strategic focus on CNS present a promising outlook for future growth.
While challenges exist in product transitions and market dynamics, Supernus is well-positioned to capitalize on opportunities in the CNS space.
By leveraging its strengths, addressing challenges, and seizing opportunities, Supernus Pharmaceuticals aims for sustained growth and market leadership.

Supernus Pharmaceuticals reports robust Q1 performance amidst pipeline opportunities

Supernus Pharmaceuticals demonstrated strong performance in Q1 2024, driven by Qelbree's growth, while facing challenges in the Parkinson's franchise.
The company's financial stability is evident with a healthy cash position and reiterated full-year revenue guidance.
Exciting opportunities exist in the CNS pipeline, but addressing setbacks like the FDA response for SPN-830 is crucial.
Strategic actions are needed to navigate the impact of generics on existing products and capitalize on upcoming catalysts.

Supernus Pharmaceuticals reports strong Q2 earnings and raises 2024 guidance

Supernus Pharmaceuticals demonstrated solid financial performance and growth in Q2 2024, driven by key products and pipeline advancements.
While facing regulatory uncertainties and operational challenges, the company's strong cash position and raised guidance signal resilience and strategic foresight.
Opportunities lie in expanding the CNS pipeline, optimizing gross-to-net deductions, and leveraging financial strength for future growth initiatives.

Supernus Pharmaceuticals reports strong Q3 performance and raises revenue guidance

Supernus Pharmaceuticals demonstrated robust financial performance and product growth in Q3 2024, driven by key products and pipeline advancements.
While facing challenges with certain product sales and pricing strategies, the company remains well-positioned for future opportunities and revenue expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Peter Vozzo - Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler Jack Padovano - Stifel Operator Good afternoon, and welcome to Supernus Pharmaceuticals' First Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q1 2022 Results - Earnings Call Transcript

ROCKVILLE, Md., May 09, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced preliminary financial results for the first quarter of 2022, and associated Company developments.

Supernus Announces First Quarter 2022 Financial Results

ROCKVILLE, Md., May 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the first quarter of 2022 after the market closes on Monday, May 9, 2022.

Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022

The FDA approved an expanded indication for Supernus Pharmaceuticals Inc's (NASDAQ: SUPN) Qelbree (viloxazine extended-release capsules) for attention deficit hyperactivity disorder (ADHD) in adult patients aged 18 and older. The FDA has now approved Qelbree for ADHD in.

FDA Approves Expanded Use Of Supernus' Viloxazine In Adult ADHD Patients

First novel, nonstimulant option for adults with ADHD in 20 years ADHD affects an estimated 10 million adults in the U.S. ROCKVILLE, Md. , May 2, 2022 /PRNewswire/ -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Qelbree (viloxazine extended-release capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adult patients aged 18 and older.

Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults

ROCKVILLE, Md., April 13, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today filed its Annual Report on Form 10-K and reported final audited financial results for the fourth quarter and full year ended December 31, 2021.

Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results

ROCKVILLE, Md., April 04, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it expected to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “Annual Report”) in the near term.

Supernus Provides Update on Filing of Annual Report and Reiterates Full Year 2022 Financial Guidance

ROCKVILLE, Md., March 17, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, filed a notification of Late Filing on Form 12b-25 on March 1, 2022, indicating that the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “Annual Report”) would be delayed. Today, Supernus notified the Nasdaq Listing Qualifications Department that it is not in compliance with the filing requirement under Nasdaq Rule 5250(c)(1) due to its failure to timely file its Annual Report. Supernus currently anticipates filing its Annual Report on or before April 4, 2022 and thereby regaining compliance with the filing requirement.

Supernus Notifies Nasdaq Regarding Non-Compliance with Listing Requirement and Expectation to Regain Compliance

ROCKVILLE, Md., March 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat as part of the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022, at 1:30 p.m. ET.

Supernus to Participate in Annual Cowen Health Care Conference

Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q4 2021 Results - Earnings Call Transcript

ROCKVILLE, Md., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced preliminary financial results for the fourth quarter and full year of 2021, and associated Company developments.

Supernus Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results

ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report preliminary fourth quarter and full year 2021 financial results and full year 2022 financial guidance after the market closes on Monday, February 28, 2022.

Supernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022

Supernus (SUPN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Supernus (SUPN) Moves 5.7% Higher: Will This Strength Last?

Supernus (SUPN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for Supernus (SUPN)

The attack had no significant impact on the business and did not cause any significant disruption to Company's operations

Supernus Pharmaceuticals Targeted in Ransomware Incident

Acquisition strengthens Parkinson's disease portfolio and diversifies revenue and cash flow Acquisition strengthens Parkinson's disease portfolio and diversifies revenue and cash flow

Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus' proposed acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) expired at 11:59 p.m. on November 22, 2021.

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer

ROCKVILLE, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will participate and host investor meetings at the following upcoming November 2021 investor conferences.

Supernus to Participate in Upcoming November Investor Conferences

Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q3 2021 Results - Earnings Call Transcript

Supernus (SUPN) delivered earnings and revenue surprises of 90.48% and 5.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Supernus Pharmaceuticals (SUPN) Q3 Earnings and Revenues Beat Estimates

Supernus Pharmaceuticals (NASDAQ:SUPN) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

Supernus Pharmaceuticals: Q3 Earnings Insights

ROCKVILLE, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today reported financial results for the third quarter of 2021, and associated Company developments.

Supernus Announces Third Quarter 2021 Financial Results

ROCKVILLE, Md., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the third quarter of 2021 after the market closes on Wednesday, November 3, 2021.

Supernus to Announce Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021

Adamas Pharmaceuticals

Adamas looks like a good fit for Supernus.

Why Supernus' Acquisition of Adamas Is a Smart Move

NEW YORK, Oct. 11, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company") (NASDAQ: ADMS) in connection with the proposed acquisition of the Company by Supernus Pharmaceuticals, Inc. ("Supernus") (NASDAQ: SUPN), via a tender offer.  Under the terms of the merger agreement, the Company's shareholders will receive $8.10 per share in cash payable at closing, plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash, payable upon achieving certain net sales thresholds of the Company's lead product, GOCOVRI, for each share of Adamas common stock that they hold.

News for Supernus Pharmaceuticals Stock (SUPN)